Impact of Persistence with Tumour Necrosis Factor Inhibitors on Healthcare Resource Utilization and Costs in Chronic Inflammatory Joint Diseases - Sorbonne Université Access content directly
Journal Articles British Journal of Clinical Pharmacology Year : 2021

Impact of Persistence with Tumour Necrosis Factor Inhibitors on Healthcare Resource Utilization and Costs in Chronic Inflammatory Joint Diseases

Abstract

Aim: To assess persistence with subcutaneous (SC) tumour necrosis factor (TNF) inhibitors as well as the impact of persistence on healthcare resource utilization (HCRU) and costs in patients with chronic inflammatory joint diseases. Methods: In this cohort study using population-based French claims data (from 2011 to 2014), we measured persistence with SC TNF inhibitors within 12 months (M0-12) following treatment initiation in treatment-naïve and treatment-experienced users (divided into three cohorts: rheumatoid arthritis [RA], ankylosing spondylitis [AS] and psoriatic arthritis [PsA]). Persistent patients were propensity score matched to nonpersistent patients at M12. The impact of persistence status on HCRU and costs was assessed during M12-24. Results: Of treatment-naïve (n = 3,804) and treatment-experienced (n = 2,279) users, only 56.1% and 46.8% were persistent at M12, respectively. Nonpersistent patients had more outpatient visits, computerized tomography scans, spine or joint magnetic resonance imaging procedures and disease-related hospitalizations, while persistent patients had more rheumatologist visits. Nonpersistent patients had lower drug costs but higher nondrug-related healthcare and hospitalization costs than persistent patients. In AS and PsA, overall healthcare costs were similar in persistent and nonpersistent patients. In RA, overall healthcare costs were lower in persistent patients (15,753€ vs 17,590€ in treatment-naïve and 17,622€ vs 21,177€ in treatment-experienced). Conclusion: Persistence with SC TNF inhibitors within first 12 months following treatment initiation was low in both treatment-naïve and treatment-experienced patients. Differences were observed in distribution of costs between persistent and nonpersistent patients, showing that nonpersistence with SC TNF inhibitors can lead to increased HCRU and higher costs.

Dates and versions

hal-03892147 , version 1 (09-12-2022)

Identifiers

Cite

Manon Belhassen, Florence Tubach, Christophe Hudry, Macha Woronoff-Lemsi, Laurie Levy-Bachelot, et al.. Impact of Persistence with Tumour Necrosis Factor Inhibitors on Healthcare Resource Utilization and Costs in Chronic Inflammatory Joint Diseases. British Journal of Clinical Pharmacology, 2021, 87 (1), pp.163--177. ⟨10.1111/bcp.14387⟩. ⟨hal-03892147⟩
9 View
0 Download

Altmetric

Share

Gmail Facebook X LinkedIn More